Articles & Blogs

NULISA, Simoa and MSD are all sensitive immunoassay technologies, but they are not interchangeable. Each platform has different strengths in sensitivity, multiplexing, assay availability, sample requirements, quantification and customisation. The right choice therefore depends on more than selecting the platform with the highest stated sensitivity or largest panel.

Biomarker studies are increasingly expected to generate deeper biological insight from limited material. Longitudinal studies, archived specimens, rare-disease cohorts and difficult-to-collect biofluids can all restrict the sample volume available for analysis.

Established biomarkers provide valuable insights, but measuring them in isolation may not capture disease heterogeneity or the wider biological response.